COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer.

Selective cyclooxygenase (COX)-2-inhibiting and other nonsteroidal anti-inflammatory drugs (NSAIDs) show promise for preventing and treating bladder and prostate cancers. In contrast to the strong NSAID epidemiology in colorectal cancer, the epidemiologic data on NSAIDs and genitourinary (GU) cancers are limited and mixed. However, a substantial body of preclinical in vitro and in vivo animal model data shows consistent NSAID activity in treating, and in some cases preventing, GU cancers and begins to address the mechanisms behind this activity (eg, involving Akt and ERK2 in the prostate). Many preclinical and clinical NSAID studies currently under way are helping to resolve the best type (selective or nonselective COX inhibitors or non-COX inhibitors), dose and duration of NSAID treatment for prevention in the GU setting. Future studies likely will focus on clarifying the NSAID mechanisms behind and developing NSAID combinations for both treating and preventing GU cancers.

[1]  H. Knispel,et al.  Acetylsalicylic acid inhibition of n-butyl-(4-hydroxybutyl) nitrosamine-induced bladder carcinogenesis in rats , 2005, Journal of Cancer Research and Clinical Oncology.

[2]  Wei Zhao,et al.  Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US , 2002, Cancer Causes & Control.

[3]  T. Wheeler,et al.  Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. , 2003, The Journal of urology.

[4]  Y. Mizutani,et al.  Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. , 2002, The Journal of urology.

[5]  F. Bladou,et al.  Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. , 2002, The Journal of urology.

[6]  W. Willett,et al.  Aspirin use in relation to risk of prostate cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  Xueqin Song,et al.  Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. , 2002, Journal of the National Cancer Institute.

[8]  R. Roberts,et al.  A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. , 2002, Mayo Clinic proceedings.

[9]  Xìao-chun Xu.  COX-2 inhibitors in cancer treatment and prevention, a recent development. , 2002, Anti-cancer drugs.

[10]  B. Craig,et al.  Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. , 2002, Cancer research.

[11]  L. Dennis,et al.  Meta-Analysis of Measures of Sexual Activity and Prostate Cancer , 2002, Epidemiology.

[12]  W. Isaacs,et al.  Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. , 2001, Cancer Research.

[13]  G. Stamp,et al.  Cyclooxygenase‐2: a possible target in schistosoma‐associated bladder cancer , 2001, BJU international.

[14]  A. Partin,et al.  Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. , 2001, The Journal of urology.

[15]  N. Altorki,et al.  Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. , 2001, The Lancet. Oncology.

[16]  H. Frucht,et al.  Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. , 2001, Carcinogenesis.

[17]  J. Lewin,et al.  Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Amling.  Diagnosis and management of superficial bladder cancer. , 2001, Current problems in cancer.

[19]  S. Akiba,et al.  Relation between cyclooxygenase‐2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder , 2001, Cancer.

[20]  A. Klein-Szanto,et al.  Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. , 2001, Cancer research.

[21]  H. Sano,et al.  Expression of cyclooxygenase-2 in patients with bladder carcinoma. , 2001, The Journal of urology.

[22]  A. Sabichi,et al.  Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. , 2001, Cancer research.

[23]  S. Nordling,et al.  Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. , 2001, The American journal of pathology.

[24]  C. Sakakura,et al.  Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  P. Boström,et al.  EXPRESSION OF CYCLOOXYGENASE‐1 AND‐2 IN URINARY BLADDER CARCINOMAS IN VIVO AND IN VITRO AND PROSTAGLANDIN E 2 SYNTHESIS IN CULTURED BLADDER CANCER CELLS , 2001, Pathology.

[26]  Rajnish A. Gupta,et al.  15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. , 2001, Cancer research.

[27]  B. Teicher,et al.  Cyclooxygenase inhibitors are potent sensitizers of prostate tumours to hyperthermia and radiation. , 2001, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[28]  R. Roberts,et al.  Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. , 2001, Neoplasia.

[29]  V. Steele,et al.  Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. , 2000, Cancer research.

[30]  R A Stephenson,et al.  Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. , 2000, Journal of the National Cancer Institute.

[31]  A. Levine,et al.  Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. , 2000, The Journal of urology.

[32]  C. King,et al.  Predisposition to urinary tract epithelial metaplasia in Schistosoma haematobium infection. , 2000, The American journal of tropical medicine and hygiene.

[33]  C. Coffey,et al.  Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. , 2000, Human pathology.

[34]  Y. Shyr,et al.  Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. , 2000, The American journal of pathology.

[35]  R. Lancashire,et al.  Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database , 2000, BMJ : British Medical Journal.

[36]  T. Shirahama,et al.  Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  D. Knapp,et al.  Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. , 2000, American journal of veterinary research.

[38]  R. Greenberg,et al.  Intravesical therapy for superficial bladder cancer. , 2000, Oncology.

[39]  N. Greenberg,et al.  E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. , 2000, Cancer research.

[40]  M. Yu,et al.  Non-steroidal anti-inflammatory drugs and bladder cancer prevention , 2000, British Journal of Cancer.

[41]  K. Loughlin,et al.  An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. , 2000, The Urologic clinics of North America.

[42]  R A Stephenson,et al.  Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.

[43]  R. Hayes,et al.  Sexual behaviour, STDs and risks for prostate cancer , 2000, British Journal of Cancer.

[44]  V. Serretta,et al.  Pure Squamous Cell Carcinoma of the Bladder in Western Countries , 2000, European Urology.

[45]  Randall Harris,et al.  Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. , 2000, Oncology reports.

[46]  J. Baron,et al.  Nonsteroidal anti-inflammatory drugs and cancer prevention. , 2000, Annual review of medicine.

[47]  T. Kuczek,et al.  Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer , 2000, Cancer Chemotherapy and Pharmacology.

[48]  J. Epstein,et al.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.

[49]  D. Bostwick,et al.  Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. , 1999, Cancer research.

[50]  A. Brash,et al.  15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. , 1999, The American journal of pathology.

[51]  D. Heitjan,et al.  Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. , 1999, Urology.

[52]  K. Wakabayashi,et al.  Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. , 1998, Cancer research.

[53]  K. Kinzler,et al.  Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[54]  E. Okajima,et al.  Chemopreventive Efficacy of Piroxicam Administered Alone or in Combination with Lycopene and β‐Carotene on the Development of Rat Urinary Bladder Carcinoma after A N‐Butyl‐N‐(4‐hydroxybutyl)nitrosamine Treatment , 1997, Japanese journal of cancer research : Gann.

[55]  T. Shirai,et al.  Lack of involvement of p53 gene mutations in N-methyl-N-nitrosourea-induced bladder tumor progression in N-butyl-N-(4-hydroxybutyl)nitrosamine-treated rats and no suppression by indomethacin. , 1997, Cancer letters.

[56]  V. Steele,et al.  Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. , 1996, Carcinogenesis.

[57]  S. Johansson,et al.  Effect of indomethacin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced urinary tract carcinogenesis. , 1995, Carcinogenesis.

[58]  C. Rao,et al.  Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. , 1995, Cancer research.

[59]  T. Kuczek,et al.  Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. , 1994, Journal of veterinary internal medicine.

[60]  S. Fukushima,et al.  Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogenesis model , 1993, International journal of cancer.

[61]  V. Steele,et al.  Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. , 1993, Carcinogenesis.

[62]  V. Steele,et al.  Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors. , 1993, Anticancer research.

[63]  S. Cohen,et al.  Effect of aspirin on urinary bladder carcinogenesis initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in rats. , 1989, Cancer research.

[64]  S. Cohen,et al.  Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats. , 1986, Cancer research.

[65]  M. Pollard,et al.  The beneficial effects of diphosphonate and piroxicam on the osteolytic and metastatic spread of rat prostate carcinoma cells , 1986 .

[66]  J. Drago,et al.  The effect of prostaglandin modulators on prostate tumor growth and metastasis. , 1984, Anticancer research.

[67]  J. Drago,et al.  Control of metastases in the Nb rat prostatic adenocarcinoma model. , 1984, Journal of andrology.

[68]  M. Droller,et al.  Indomethacin and poly I:C in the inhibition of carcinogen-induced bladder cancer in an experimental animal model. , 1984, The Journal of urology.

[69]  S. Cohen,et al.  Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat. , 1984, Cancer letters.

[70]  S. Cohen,et al.  Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide-induced bladder carcinogenesis and enhancement of forestomach carcinogenesis. , 1984, Carcinogenesis.

[71]  J. Drago,et al.  Nb rat prostate adenocarcinoma model androgen‐sensitive tumor: Metastasis control , 1983, Journal of surgical oncology.

[72]  M. Droller,et al.  Inhibition of tumor growth in association with modification of in vivo immune response by indomethacin and polyinosinic:polycytidylic acid. , 1982, Cancer research.

[73]  M. Droller,et al.  Interferon induction and prostaglandin synthetase inhibition in the in vitro and in vivo manipulation of immune response expression in an animal model of bladder cancer. , 1982, Cellular immunology.

[74]  S. Cohen,et al.  Aspirin inhibition of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase. , 1981, Cancer research.

[75]  M. Pollard,et al.  Investigations on prostatic adenocarcinomas in rats. , 1977, Oncology.